Scroll Top

BrainEver

Stopping age-related brain pathologies.

BrainEver

brainever

SECTEUR

Biotech

Approche

Homéoprotéines

Indication

Maladies Neurodégénératives (Parkinson, SLA)

Founded in 2016 by Prof. Alain Prochiantz, and Bernard Gilly, BrainEver is a biotechnology company specializing in the discovery and development of innovative treatments for neurodegenerative diseases.

BrainEver exploits the intrinsic properties of homeoproteins, a family of transcription factors essential during embryonic and postnatal development, and which recent studies have shown to play a key role in the maintenance and adult survival of specific neuronal populations. An important property of homeoproteins is their ability to penetrate cells, with privileged access to cytoplasmic and nuclear compartments. They therefore require no transport system to reach targeted cells.
divider